PARADOXical Low Flow Low Gradient Aortic Stenosisの経カテーテル弁修復の有無にかかわらず、最適な医療処置による利益の正確な評価 (REBOOT-PARADOX)
症候性の逆説的な低流量、低勾配大動脈弁狭窄症患者における弁修復の有無にかかわらず最適な治療 - 多施設無作為化比較
Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.
調査の概要
詳細な説明
Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood flow from the heart into the Aorta, and is associated with symptoms like fatigue, breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged aortic valve has been proven to be a safe and effective treatment option.
Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation from the usually observed disease pattern: These patients do not show the typical high pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular gradient; "paradoxical" low flow/low gradient aortic stenosis). For these patients it is not yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair - TAVR) should be a treatment option as well.
REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment alone for patients suffering from paradoxical aortic stenosis. Two thirds of the participating patients will be treated by TAVR, one third will receive medical Treatment alone.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Milan、イタリア、20089
- Humanitas Mirasole S.P.A
-
Pisa、イタリア、56126
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
-
Zurich、スイス、8091
- Universitätsspital Zürich, Universitätres Herzzentrum Zürich
-
-
-
-
Baden-Wurttemberg
-
Tübingen、Baden-Wurttemberg、ドイツ、72076
- Universitätsklinikum Tübingen
-
-
Bavaria
-
München、Bavaria、ドイツ、80636
- Deutsches Herzzentrum München
-
München、Bavaria、ドイツ、81377
- Klinikum der Universität München-Großhadern
-
-
Free and Hanseatic City of Hamburg
-
Hamburg、Free and Hanseatic City of Hamburg、ドイツ、20246
- Universitäres Herz- u. Gefäßzentrum Hamburg
-
-
Hesse
-
Bad Nauheim、Hesse、ドイツ
- Kerckhoff-Klinik GmbH
-
-
Lower Saxony
-
Bad Bevensen、Lower Saxony、ドイツ、29549
- Herz- und Gefäßzentrum Bad Bevensen
-
-
Mecklenburg-Vorpommern
-
Rostock、Mecklenburg-Vorpommern、ドイツ、18057
- Universitätsmedizin Rostock, Klinik und Poliklinik für Kardiologie
-
-
North Rhine-Westphalia
-
Bad Oeynhausen、North Rhine-Westphalia、ドイツ、32545
- Herz- und Diabeteszentrum Nordrhein-Westfalen Bad Oeynhausen
-
Cologne、North Rhine-Westphalia、ドイツ、50937
- Herzzentrum der Universität Köln
-
-
Rhineland-Palatinate
-
Ludwigshafen am Rhein、Rhineland-Palatinate、ドイツ
- Klinikum der Stadt Ludwigshafen a. Rh.
-
-
Saxony
-
Leipzig、Saxony、ドイツ
- Herzzentrum Leipzig
-
-
Schleswig-Holstein
-
Bad Segeberg、Schleswig-Holstein、ドイツ
- Segeberger Kliniken, Herzzentrum
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- I1. Patients with symptomatic native aortic valve stenosis and age ≥18 years
- I2. Aortic valve area (AVA) ≤ 1 cm2 or indexed AVA ≤ 0.6 cm2/m2, mean aortic gradient < 40 mmHg and stroke volume index (SVI) < 35ml/m2
- I3. Left ventricular ejection fraction ≥ 50%
- I4. MDCT aortic valve calcium score men > 2000AU, women > 1200AU OR the likelihood criteria are fulfilled (symptoms without other explanation and LV hypertrophy; age < 70 yrs., AVS < 0.8 cm2; SVI < 35ml/m2 confirmed by 3D TOE, MRI or invasive; reduced LV longitudinal function without other reason)
- I5. Heart team agrees on eligibility for TAVR
- I6. Written informed consent
- I7. Negative pregnancy test in women with childbearing potential
Exclusion Criteria:
- E1. Hemodynamic instability
- E2. Cardiogenic shock
- E3. Pre-existing mechanical or bio-prosthetic valve in any position
- E4. Concomitant severe valvular heart disease
- E5. Pre-existing or active endocarditis
- E6. Need for heart surgery due to other conditions
- E7. Aortic valve is congenital unicuspid or congenital bicuspid
- E8. Hypertrophic cardiomyopathy with or without obstruction
- E9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- E10. Acute myocardial infarction within 1 month before intended AS-treatment
- E11. Renal replacement therapy
- E12. Estimated life expectancy < 24 months (730 days) due to carcinomas end stage liver disease or renal disease
- E13. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- E14. Patient refuses aortic valve repair
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:TAVR Group
Patients will be treated by transcatheter aortic valve repair (TAVR). |
Repair of defective aortic valve by microsurgical Intervention. |
|
介入なし:Medical Treatment Group
Patients will receive optimal medical treatment alone. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to death
時間枠:24 months after last-patient-in
|
All-cause mortality |
24 months after last-patient-in
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cardiovascular mortality
時間枠:5 years after index treatment
|
Death because of cardiovascular events |
5 years after index treatment
|
|
Re-hospitalization due to heart failure
時間枠:5 years after index treatment
|
Number of hospital stays after randomization |
5 years after index treatment
|
|
Incidence of neurological events - incidence of strokes
時間枠:5 years after randomization
|
Number of strokes |
5 years after randomization
|
|
Incidence of neurological Events - incidence of transient ischaemic attacks
時間枠:5 years after randomization
|
Number of transient ischaemic attacks |
5 years after randomization
|
|
Cardiac functionality - left ventricular function
時間枠:5 years after randomization
|
Echocardiographic measurement of left ventricular ejection fraction in % |
5 years after randomization
|
|
Cardiac functionality - aortic valve hemodynamics
時間枠:5 years after randomization
|
Measurement of aortic pressure in mmHg |
5 years after randomization
|
|
Patients' quality of life
時間枠:5 years after randomization
|
EQ5D-score in % |
5 years after randomization
|
|
Device reliability
時間枠:5 years after randomization
|
Number of reinterventions (TAVR arm only) |
5 years after randomization
|
協力者と研究者
捜査官
- 主任研究者:Steffen Massberg, Prof. Dr.、University Clinic Munich
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。